Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis
|
|
- Octavia Richards
- 5 years ago
- Views:
Transcription
1 Indian J Med Res 120, September 2004, pp Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis Ashima Bhatia, K.D. Tripathi & Manoj Sharma* Department of Pharmacology, Maulana Azad Medical College & *Department of Radiotherapy, LN Hospital, New Delhi, India Received September 19, 2003 Background & objectives: Delayed emesis with cisplatin is a significant problem, which is often poorly controlled with conventional antiemetics. There is a relative paucity of data on the control of delayed emesis and rather inconsistent results have been reported. The present study aimed to compare the efficacy and tolerability of ondansetron versus metoclopramide in dose related grades of cisplatin-induced delayed emesis. Methods: A total of 80 chemotherapy naïve patients with malignancy were randomized to receive cisplatin 60 mg/m 2 intravenously (iv) either as a single dose on day 1 (high dose regimen) or split into three doses of 20 mg/m 2 each on 3 days (low dose regimen) along with bleomycin +5- flurouracil in 40 patients each. Patients were further randomized in each cisplatin regimen to receive either 20 mg metoclopramide (20 patients) or 8 mg ondansetron (20 patients) iv 30 min prior to cisplatin administration followed by the respective antiemetic orally 8 hourly for five days after the last cispaltin administration. Ten patients receiving high dose cisplatin in each group were also given dexamethasone 8 mg iv with the primary antiemetic. The assessment period started 24 h after last cisplatin infusion and ended at midnight on day 5. Results: In low dose cisplatin regimen, complete suppression of delayed emesis occurred in 55 per cent patients receiving ondansetron and in 30 per cent patients receiving metoclopramide. Neither ondansetron nor metoclopramide could completely suppress delayed emesis in high dose cisplatin regimen. Protection from nausea in the delayed phase was seen in 85 per cent patients receiving ondansetron and in 70 per cent patients receiving metoclopramide in low dose regimen, while nausea protection rates were 70 vs 0 per cent respectively in the high dose regimen. Addition of dexamethasone to metoclopramide significantly augmented its antiemetic efficacy (P<0.02) and the combination of metoclopramide + dexamethasone was found to be as efficacious as ondansetron monotherapy. Twenty out of 80 patients reported 39 adverse events of mild intensity. No significant effects on QOL (quality of life) parameters were observed in any group over the 5-day period. Interpretation & conclusion: The results demonstrate that delayed emesis due to cisplatin is also dose related, and superior antiemetic efficacy of ondansetron compared to metoclopramide is maintained, though its superiority is less marked than against acute emesis. Metoclopramide and dexamethasone combination matched the antiemetic efficacy of ondansetron monotherapy. Key words Cisplatin - delayed emesis - dexamethasone - metoclopramide - ondansetron 183
2 184 INDIAN J MED RES, SEPTEMBER 2004 Nausea and vomiting are the most distressing side effects of cytotoxic chemotherapy 1. In contrast to the prolonged monophasic pattern of emesis induced by agents like cyclophosphamide, cisplatin induces a biphasic pattern of emesis. The initial phase referred to as acute emesis is more severe and peaks over the first 6-8 h 2. The second phase delayed emesis, begins after 24 h and lasts for 4-5 days. Though less severe than acute emesis, it is debilitating and more resistant to conventional antiemetics 3. The overall incidence of delayed emesis and nausea has been reported to vary from 43 to 89 per cent 4-6 and its intensity peaks between 24 to 72 h following cisplatin administration 3. The pathophysiology of delayed emesis in contrast to that of acute emesis is largely undefined, though response to the antiemetic medication in the acute phase is the most important predictor for delayed emesis 7,8. The usual practice for prevention of delayed emesis is extended administration of the antiemetic for 4 to 5 days. There is paucity of data on control of delayed emesis and rather inconsistent results have been reported Efficacy of 5-hydroxytryptamine (5- HT 3 ) antagonists though established against acute emesis, is controversial against delayed emesis Moreover, there are very few studies assessing the effect of antiemetics on quality of life (QOL) of cancer patients. Further, no studies have been done to compare efficacy of antiemetics against dose related grades of delayed emesis. We have earlier reported superior antiemetic efficacy of ondansetron in comparison to metoclopramide in cisplatin induced acute emesis 15. The present study compares efficacy and tolerability of ondansetron with metoclopramide in delayed emesis induced by 60 mg/m 2 cisplatin given either as a single dose (high dose regimen) or split into multiple doses of 20 mg/m 2 over three days (low dose regimen) and their effect on QOL parameter. Dexamethasone has been reported to improve the control of nausea and vomiting by the primary antiemetic and the effect of a single dose administered before cispaltin injection may persist beyond the acute phase and help in control of delayed emesis as well Therefore, the effect of addition of dexamethasone to the primary antiemetic was also assessed. Material & Methods The study was conducted at the Department of Radiotherapy, Lok Nayak Hospital and Department of Pharmacology, Maulana Azad Medical College, New Delhi, over a period of 10 months (April 1998 to February 1999). It was a randomized, observer blind, prospective, parallel group study. The study protocol was approved by the institutional ethics committee. Written informed consent was obtained from all patients before inclusion in the study. Patients: Eighty consecutive chemotherapy naïve patients of either sex aged 18 yr or above with histologically proven malignancy and Kernofsky Performance Grade 19 of more than 60 per cent and presenting to the outdoor services of the Radiotherapy department were included in the study. Patients were excluded if any of the following applied: severe concurrent illness, vomiting due to some other cause, antiemetic therapy administered concurrently or in the 24 h preceding chemotherapy, administration of benzodiazepines except when given for night sedation, vomiting in the 24 h before chemotherapy, pregnant or lactating women, concurrent radiation therapy, impaired renal function (serum creatinine >2.0 mg/dl), jaundice (serum bilirubin >2.0 mg/dl) or an elevated aminotransferase level (SGOT/SGPT > twice the upper normal limit). Chemotherapy: All patients received a regimen consisting of cisplatin, bleomycin and 5-flurouracil, hence making the chemotherapy regimen uniform in all the patients. Patients were randomized according to a table of random numbers to receive either low dose cisplatin regimen (groups I and II) or high dose cisplatin regimen (groups III and IV). In high dose regimen,patients were given 60mg/m 2 cisplatin intravenously (iv) as a single dose on first day and in low dose regimen, cisplatin was split into three iv doses of 20 mg/m 2 each on three consecutive days. Cisplatin was administered as continuous iv infusion in a vac of dextrose-normal saline over 1 h. In addition, all patients received bleomycin 15 mg iv on first and fifth day and 5- fluorouracil 500 mg iv for five days as was required in their regimens.
3 BHATIA et al: ONDANSETRON VERSUS METOCLOPRAMIDE IN CISPLATIN-INDUCED DELAYED EMESIS Antiemetic regimens: Patients in groups I and III received metoclopramide 20 mg iv 30 min prior to each cisplatin administration followed by 20 mg metoclopramide orally eight hourly for five days after the last cisplatin administration. Patients in groups II and IV similarly received 8 mg ondansetron iv 30 min prior to each cisplatin administration followed by oral 8 mg ondansetron 8 hourly for five days. In groups III and IV, dexamethasone (8 mg iv 30 min prior to cisplatin administration) was added to the respective antiemetic regimens in ten patients each (Table I). Patients were withdrawn from the study if they had > 10 episodes of vomiting and given rescue medication according to the attending physician s discretion. Assessment: Only those patients who did not require antiemetic rescue medication during the acute phase (i.e., up to 24 h after the last cisplatin administration) were eligible to continue participation in the study for assessment of delayed emesis. The assessment period started 24 h after last cisplatin infusion and ended at midnight on day 5. Day 1 was defined as the day/days of cisplatin infusion. All patients were provided a daily diary card and asked to keep a record of the time of each emetic episode, their assessment of nausea and global satisfaction and the occurrence of any adverse effects. Additionally, a blinded observer, who was not involved in dispensing 185 of medication, independently recorded the same information daily. The same observer made all the assessments. The primary efficacy parameters were the number of emetic episodes on each study day and the severity of nausea. An emetic episode was defined as a single episode of vomiting (expulsion of stomach contents through mouth), a single episode of retching (an attempt to vomit but not productive of stomach contents) or any number continuous vomits and/or retches. Emetic episodes were by definition, separated by the absence of both vomiting and retching for at least one minute 20. The number of emetic episodes per day were used to define the daily treatment response as follows: complete response: no emetic episode: major response: 1-2 emetic episodes; minor response: 3-5 emetic episodes and failure: more than 5 emetic episodes 20. The severity of nausea was assessed by patients, independently from emesis, using a 4-point categoric scale (none: no nausea, mild: did not interfere with normal daily life; moderate: interfered with normal daily life and severe; bedridden due to nausea) 20,21. Nausea was also assessed on a mm visual analogue scale (VAS 0-no nausea to 100-extreme nausea) 21. Nausea assessments were made at the end of each study day. Table I. Group-wise chemotherapy, antiemetic regimens in patients Groups Cisplatin dose Antiemetic regimen Number of patients (Symbols used) I (M+C-20) 20mg/m 2 X 3 days Metoclopramide 20 II (O+C-20) 20mg/m 2 X 3 days Ondansetron 20 IIIa(M+C-60) 60 mg/m 2 single dose Metoclopramide 10 IIIb(M+D+C-60) 60 mg/m 2 single dose Metoclopramide + Dexa 10 IVa(O+C-60) 60 mg/m 2 single dose Ondansetron 10 IVb(O+D+C-60) 60 mg/m 2 single dose Ondansetron + Dexa 10 Dexa, dexamethasone C-20, Patients receiving low dose cisplatin; C-60, Patients receiving high dose cisplatin M, Patients receiving metoclopramide prophylaxis; O, Patients receiving ondansetron prophylaxis M+D, Patients receiving metoclopramide and dexamethasone prophylaxis O+D, Patients receiving ondansetron and dexamethasone prophylaxis
4 186 INDIAN J MED RES, SEPTEMBER 2004 Effect of therapy on food intake was graded as 1- better than usual; 2- as usual; 3- could take some solid or 4- could take only liquid 22. Global satisfaction with control of nausea and vomiting was assessed by patients, independently from emesis, at the end of the study using a 100 mm VAS (0- not at all satisfied to totally satisfied) 20,21. QOL was assessed at baseline and at the end of treatment period using Rotterdam symptoms checklist 23. Separate analyses were performed for the psychological, physical and functional activity subscales. The results of each patient were expressed on a scale of 0-3 where 0 corresponded with not at all, 1 with a little, 2 with somewhat and 3 with very much on psychological and physical indices. In the functional activity index subscale, 0 corresponded with without help, 1 with without help with difficulty, 2 with only with help and 3 with unable. Blood samples were taken before the first dose of chemotherapy and at the end of the study to monitor complete cell count and biochemistry. Adverse events were elicited by general questioning of the patients on their daily visits as well as from patients daily records. Patient compliance was checked by daily questioning and by counting the number of tablets brought back each day. Statistical analysis: Analysis for the control of delayed emesis was based on the worst day outcomes through days 2-5. Quantitative data like number of episodes of vomiting were analyzed using Student s t-test. Graded data like intensity of nausea, magnitude of antiemetic response, QOL parameters and food intake scores were analyzed using Mann- Whitney U test. The limit of significance was set at P<0.05 in all cases. Results There was no significant difference in the patient profile of different groups (Table II). Table II. Characteristics of patients in various treatment groups Group I Group II Group III Group IV M+C-20 O+C-20 M(±D) +C-60 O(±D) +C-60 (N=20) (N=20) (N=20) (N=20) Age (yr)* 45.1± ± ± ±10.3 (21-65) (24-60) (35-60) (32-63) Sex (M : F) 10:10 7:13 9:11 13:7 Malignancy Head & Neck Cervix Others Tumour surgery (Yes:No) 1:19 4:16 2:18 4:16 Alcohol intake # (none: <7U/wk: >_7U/wk) 18:2:0 15:3:2 15:3:2 16:3:1 H/o tobacco chewing (positive : negative) 3:17 4:16 6:14 4:16 Smoking (Yes : No) 9:11 8:12 9:11 13:7 Karnofsky Performance Score 97.5± ± ±4.4 96±5.0 H/o. motion sickness (Yes : No) 0:20 0:20 0:20 0:20 Description of group symbols as in Table I M(±D)+C-60 : Metoclopramide prophylaxis with or without dexamethasone in cisplatin 60 mg/m 2 group O(±D)+C-60 : Ondansetron prophylaxis with or without dexamethasone in cisplatin 60 mg/m 2 group *Values are mean ± SD (range) # Alcohol intake: 1U= 150 ml wine/500ml beer/50ml distilled spirit Values are mean ± SD
5 BHATIA et al: ONDANSETRON VERSUS METOCLOPRAMIDE IN CISPLATIN-INDUCED DELAYED EMESIS 187 Table III. Effect of different antiemetic regimens on delayed emesis, nausea, food intake and patient global satisfaction Group N Vomiting Nausea Food intake scores Patient global (mean) satisfaction No. of No. of episodes VAS scores* Day 0 Day2-5* VAS scores emetic days of vomiting* (mm) (Mean ± SD) (mean) (mean ± SE) (Mean ± SD) M+C ± ± ±15.2 O+C ± ± ±14.6 M+C ± ± ±12.4 O+C ± ± M+D+C ± ± ±16.1 O+D+C ± ± ±17 Group symbols as in Table I. VAS, Visual analogue scale; N, number of patients *Based on worst day outcome; Number of days the patient experienced emesis Comparison among groups P values Groups compared No. of emetic days No. of episodes of Intensity of nausea Patient global vomiting satisfaction M+C-20 vs O+C-20 >0.05 >0.05 >0.05 <0.05* M+C-60 vs O+C-60 <0.05* >0.05 <0.02* <0.02* M+D+C-60 vs O+D+C-60 >0.05 >0.05 >0.05 >0.05 M+D+C-60 vs O+D+C-60 >0.05 <0.05* <0.02* <0.02* M+C-60 vs M+D+C-60 >0.05 >0.05 <0.02* <0.02* O+C-60 vs O+D+C-60 >0.05 >0.05 >0.05 >0.05 M+D+C-60 vs O+C-60 >0.05 >0.05 >0.05 >0.05 M+C-20 vs M+C-60 <0.002* <0.001* <0.002* <0.002* O+C-20 vs O+C-60 <0.002* <0.05* <0.02* <0.002* *Significant values M(±D)+C-60 : Metoclopramide prophylaxis with or without dexamethasone in cisplatin 60mg/m 2 group O(±D)+C-60 : Ondansetron prophylaxis with or without dexamethasone in cisplatin 60mg/m 2 group Delayed emesis: The pattern of delayed emesis was more or less similar with all antiemetic regimens i.e., the maximum intensity of delayed emesis was reached on second or third day. Very few patients experienced emesis till the fifth day and these were patients on high dose cisplatin regimen receiving metoclopramide prophylaxis. The number of emetic episodes on the worst day were dependent on the cisplatin regimen. More episodes were observed in patients on high dose regimen as compared to low dose regimen (Table III). In patients receiving the low dose regimen, complete suppression was achieved in 11 (55%) patients on ondansetron prophylaxis and 6 (30%) on metoclopramide prophylaxis (Fig.1). Though the antiemetic response of ondansetron was significantly superior to metoclopramide in high dose cisplatin regimen (P<0.05), none of the two antiemetics could completely suppress emesis in these patients. Dexamethasone significantly potentiated the antiemetic response of metoclopramide (P<0.02) and the response of the combination matched that of ondansetron (Table III). Nausea accompanying delayed emesis: Intensity of nausea in the delayed phase was greater in patients on high dose cisplatin regimen (Table III; Fig.2). Ondansetron and metoclopramide decreased the intensity in patients on low dose regimen but only ondansetron proved effective in case of patients on high dose cisplatin regimen. Dexamethasone significantly augmented efficacy of metoclopramide (P<0.02) and the combination matched the efficacy
6 188 INDIAN J MED RES, SEPTEMBER 2004 Antiemetic regimen* Fig.1. Antiemetic responses obtained with metoclopramide or ondansetron with or without dexamethasone. Foot note: *Group symbols as described in Table I. Antiemetic regimen* Fig.2. Intensity of nausea observed with metoclopramide or ondansetron with or without dexamethasone. Foot note: *Group symbols as described in Table I.
7 BHATIA et al: ONDANSETRON VERSUS METOCLOPRAMIDE IN CISPLATIN-INDUCED DELAYED EMESIS of ondansetron monotherapy in protection against nausea. Food intake: Over the five days of the study, there was no appreciable change in food intake of patients on low dose cisplatin regimen (Table III). However, in the patients on high dose regimen there was little deterioration of the scores but not of statistical significance. The deterioration was marginally greater in the metoclopramide group. Addition of dexamethasone prevented this deterioration. Quality of life (QOL): QOL scores were calculated separately for psychological, physical and functional subscales (Table IV). There was a tendency towards improvement in the psychological subscale in almost all the groups though no significant differences among the groups were seen. The indices that showed improvement were mainly anxiety, loneliness, worry and desperation about future. No consistent trend was seen in the physical subscale. The indices mainly affected were loss of appetite, feeling of dizziness, inability to sleep and loss of energy. Patients receiving high dose cisplatin showed deterioration irrespective of the primary antiemetic, but the addition of dexamethasone prevented the deterioration. The functional subscale remained unchanged in all the study groups. 189 Adverse effect profile: A total of 39 adverse events were reported by 20 patients (Table V). The incidence was thus 25 per cent. Seven out of 40 patients receiving ondansetron had constipation and five out of 40 patients receiving metoclopramide complained of weakness. All the adverse events were mild and did not need discontinuation of the drug. No dystonic reaction was noted in any of the patients given metoclopramide. There was no significant change in any biochemical or haematological values of the patients from baseline. Patient global satisfaction: Patient satisfaction with the antiemetic therapy was elicited on last day of the study (Table III). In low dose cisplatin regimen, there was no statistically significant difference in global satisfaction in patients receiving metoclopramide or ondansetron. In high dose cisplatin regimen, patients receiving ondansetron prophylaxis were more satisfied with their antiemetic compared to those receiving metoclopramide (P<0.02). Addition of dexamethasone to both metoclopramide (P<0.05) and ondansetron (P=NS) improved patient satisfaction. Patient satisfaction with dexamethasone + metoclopramide combination matched that of ondansetron. Table IV. Effect of cisplatin based chemotherapy and antiemetics on quality of life scores in cancer patients Group* N Mean value of quality of life scores Psychological subscale Physical subscale Functional subscale Day 0 Day 5 Day 0 Day 5 Day 0 Day 5 M+C O+C M+C O+C M+D+C O+D+C *Group symbols as in Table I; N, Number of patients No statistically significant differences
8 190 INDIAN J MED RES, SEPTEMBER 2004 Table V. Adverse effect profile of different anti emetic regimens in cisplatin based chemotherapy recipients Number of patients reporting each side effect Side effect M+C-20 O+C-20 M+C-60 O+C-60 M+D+C-60 O+D+C-60 (n=20) (n=20) (n=10) (n=10) (n=10) (n=10) Dystonia/Akathisia Constipation Headache Heart burn Weakness Epigastric pain Nervousness Group symbols as described in Table I Discussion There is paucity of studies comparing efficacy of a 5HT 3 antagonist containing regimen with the widely used metoclopramide monotherapy regimen as well as with mertoclopramide + dexamethasone combination in cisplatin induced delayed emesis in Indian patients. There is one Indian study by Advani et al 24 who have used a wide dosage range of cisplatin ( mg/m 2 ) and a variety of chemotherapy regimens which makes the emetogenecity variable and hence difficult to interpret. In the present study efficacy and tolerability of ondansetron were compared with metoclopramide as well as the effect of addition of dexamethasone to the primary antiemetic in cisplatin-induced delayed emesis. Since emetogenicity of cisplatin is dose dependent 12,14, and efficacy of antiemetics may differ according to the intensity of emetogenic stimulus, it was decided to study the antiemetic efficacy of metoclopramide and ondansetron against a high dose regimen (60 mg/m 2 iv single dose) and a low dose regimen (20 mg/m 2 iv in 3 daily doses) of cisplatin. Assessment criteria taken for comparison of various antiemetics used in the present study were based on those already established in earlier studies 9, The maximum intensity of delayed emesis was observed on second or third day. These results support earlier observations made by Kris et al 3 who reported the highest incidence and severity of delayed emesis h after cisplatin administration. High dose cisplatin regimen was more emetogenic than low dose cisplatin regimen. The dose dependency of delayed emesis has been reported earlier 12,14. Though ondansetron was superior to metoclopramide in control of delayed emesis, the difference did not reach statistical significance. Neither metoclopramide nor ondansetron could provide complete protection against delayed emesis in the high dose cisplatin regimen. Earlier workers 5,11,25,26 have reported conflicting results with ondansetron in delayed emesis. Kris et al 25 found that only 15 per cent of patients given cisplatin ( 100 mg/m 2 ) and ondansetron were free from delayed emesis. This was not different from a placebo response rate of 11 per cent found by the same authors in their earlier study 5. De Mulder et al 11 noted no difference in efficacy between ondansetron and metoclopramide in control of delayed emesis in patients receiving a median cisplatin dose of 75 mg/ m 2. Also in a trial conducted by the Italian group of antiemetic research 8, both ondanseton and metoclopramide offered similar protection from delayed emesis. Whereas, in case of cisplatin induced acute emesis, studies have reported protection rates with ondansetron monotherapy as high as 75 per cent with a dose of cisplatin in the range of mg/ m 2,11. In our study 15 on cisplatin induced acute emesis, the protection rates with ondansetron and metoclopramide were 65 vs 30 per cent (P<0.02) in low dose cisplatin regimen and 20 per cent vs 0 per cent (P<0.02) in high dose cisplatin regimen, respectively.
9 BHATIA et al: ONDANSETRON VERSUS METOCLOPRAMIDE IN CISPLATIN-INDUCED DELAYED EMESIS Addition of dexamethasone improved the antiemetic response to metoclopramide. The improvement in response to ondansetron was also appreciable though not statistically significant. Potentiation of response to metoclopramide by dexamethasone has been reported earlier 11. In the present study, the combination of metoclopramide plus dexamethasone was found to be as efficacious as ondansetron alone in control of delayed emesis. This result is in contrast to that of Lim et al 27 who found ondansetron alone to be superior to the combination especially on days 2 and 4, despite using a higher dose of metoclopramide than in the present study. Potentiation of antiemetic regimens by addition of a single dose of dexamethasone reflects an antiemetic effect of dexamethasone beyond day 1, resulting in a lower incidence of delayed emesis. This effect of dexamethasone could also be a result of enhanced control of acute emesis. Better control of acute emesis has been found to be associated with milder delayed emesis 8. The suppression of nausea accompanying delayed emesis was parallel to the control of delayed emesis. Ondansetron was superior to metoclopramide in providing protection against nausea (protection i.e., mild/no nausea: (17 out of 20 patients) 85 per cent vs (14 out of 20 patients) 70 per cent against low dose regimen and (7 out of 10 patients) 70 per cent vs zero against high dose regimen. The results were similar to our earlier results 15 in cisplatin induced acute emesis. Dexamethasone potentiated the action of metoclopramide and ondansetron against delayed nausea. Combination of dexamethasone and metoclopramide achieved 70 per cent protection while dexamethasone plus ondansetron was effective in 80 per cent patients. The beneficial effect of dexamethasone in delayed nausea has been reported earlier by Roila and co-workers 6. We observed a direct but marginal association between emetic control and the food intake scores in different antiemetic regimens. While there was no deterioration of the scores in patients on low dose cisplatin regimen, patients on high dose regimen, especially the ones given metoclopramide prophylaxis, had more severe emesis and their food intake scores were lower. Comparable results have been reported 191 by Lee et al 22 who graded food intake scores by the same method as followed in the present study. Very few studies have been done to assess the role of antiemetics on QOL of cancer patients. We have used Rotterdam Symptom Checklist 23 to assess the effect of antiemetic regimens on QOL. However, since our study covered a period of only five to eight days, changes in QOL of patients were not very apparent over the study period. An earlier study 28 assessed the QOL in patients of breast cancer receiving cyclophosphamide over 6 courses of chemotherapy using the same questionnaire used in the present study and found that patients receiving ondansetron had better QOL compared to those receiving metoclopramide. Patient preference for ondansetron as opposed to metoclopramide was clear in both low and high dose cisplatin regimens. The present findings are different from some earlier reports 8,11 in which both ondansetron and metoclopramide were found to be equally satisfactory. This disparity could be due to the high doses of metoclopramide employed in the other studies. Patient satisfaction improved on the addition of dexamethasone to metoclopramide against high dose cisplatin regimen which confirms some earlier studies Strum et al 32 have pointed out that subjective improvement occurs on addition of corticosteroids even when objective measures of emesis do not improve. All the antiemetics used in the present study were equally well tolerated. It was very difficult to differentiate the side effects due to chemotherapy from those due to antiemetics used since both were given concurrently. Constipation was reported in seven of the 40 patients receiving ondansetron. Constipation with ondansetron has been reported earlier 33. It is noteworthy that extrapyramidal side effects did not occur in any of the patients receiving metoclopramide. The dose of metoclopramide used in the present study appears not to produce acute dystonic reactions in adult patients. In conclusion, though ondansetron proved superior to metoclopramide for control of delayed emesis, a substantial number of patients suffered from nausea and vomiting especially with high dose regimen. The
10 192 INDIAN J MED RES, SEPTEMBER 2004 efficacy of ondansetron in delayed emesis was not as good as that in acute emesis. The present findings support the contention that additional mechanisms, not involving 5HT 3 receptors may play a role in cisplatin induced delayed emesis 7,25. Another important finding is the similar efficacy of metoclopramide and dexamethasone combination to ondansetron monotherapy. In view of the lower cost of metoclopramide plus dexamethasone, this antiemetic regimen may be more affordable among Indian patients. However, further studies with larger sample size are needed to confirm these findings. References 1. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, et al. On the receiving end-patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19 : Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322 : Kris MG, Gralla RJ, Clark RA, Tyson LB, O Connell JP, Wertheim MS, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high dose cisplatin. J Clin Oncol 1985; 3 : Gandara DR. Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer 1991; 27 (Suppl 1) : S Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting : double blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7 : Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 1991; 14 : Clark RA, Gralla RJ. Delayed emesis: A dilemma in antiemetic control. Support Care Cancer 1993; 1 : Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian group for Antiemetic Research. J Clin Oncol 1997; 15 : Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13 : Johnston D, Latreille J, Laberge F. Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy. A study by the National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol 1995; 14 : de Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, et al. Ondansetron compared with high dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind crossover study. Ann Intern Med 1990; 113 : Passalacqua R, Cocconi G, Bella M, Monici L, Michiara M, Bandini N, et al. Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin : comparison of placebo vs. adrenocorticotropic hormone (ACTH). Ann Oncol 1992; 3 : Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tamura T, Fijiwara Y, et al. Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. Jpn J Clin Oncol 1989; 19 : Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, et al. The delayed emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 1992; 19 (4, Suppl 10) : Bhatia A, Tripathi KD, Sharma M. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose and high dose cisplatin chemotherapy. Indian J Med Res 2003; 118 : Roila F, Tonato M, Cognetti E, Cortesi F, Favalli G, Marangolo M, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9 : Rosell R, Abad-Esteve A, Ribas-Mundo M, Moreno I. Evaluation of a combination of antiemetic regimen including IV high-dose metoclopramide, dexamethasone, and diphenhydramine in cisplatin-based chemotherapy regimens. Cancer Treat Rep 1985; 69 : Smyth JF, Coleman RE, Nicolson M, Gallmeier WM, Leonard RC, Cornbleet MA, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J 1991; 303 : Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Maclleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949 p Olver LN. Methodology in antiemetic trials. Oncology 1992; 49 :
11 BHATIA et al: ONDANSETRON VERSUS METOCLOPRAMIDE IN CISPLATIN-INDUCED DELAYED EMESIS Del Favero AD, Roila F, Basurto C, Minott V, Ballatori E, Patoia L, et al. Assessment of nausea. Eur J Clin Pharmacol 1990; 38 : Lee CW, Suh CW, Lee JS, Lee KH, Cho GY, Kim SW, et al. Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin induced emesis. J Korean Med Sci 1994; 9 : Kaasa S. Measurement of quality of life in clinical trials. Oncology 1992; 49 : Advani SH, Gopal R, Dhar AK, Lal HM, Cooverji ND. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin. J Assoc Physicians India 1996; 44 : Kris MG, Tyson LB, Clark RA, Gralla RJ. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. Cancer 1992; 70 (4 Suppl 1) : Hesketh P. Management of cisplatin-induced delayed emesis. Oncology 1996; 53(Suppl I) : Lim AK, Haron MR, Yap TM. Ondansetron against metoclopramide/dexamethasone - a comparative study. Med J Malaysia 1994; 49 : Soukop M, McQuade B, Hunter E, Stewart A, Kaye S, Cassidy J, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 1992; 49 : Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, Reilly LK, et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 1985; 55 : Allan SG, Cornbleet MA, Warrington PS, Golland IM, Leonard RC, Smyth JN. Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. BMJ 1984; 289 : Bruera ED, Roca E, Cedaro L, Chacon R, Estevez R. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep 1983; 67 : Strum SB, McDermed JE, Liponi DF. High-dose intravenous metoclopramide versus combination highdose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy. J Clin Oncol 1985; 3 : Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989; 25 (Suppl 1): S Reprint requests: Dr Ashima Bhatia, D-1/B, 39-C, SFS DDA Flats, Janakpuri, New Delhi , India docbha@yahoo.com
Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy
Indian J Med Res 118, July 2003, pp 33-41 Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy Ashima Bhatia, K.D. Tripathi
More informationPing-Tsung Chen, MD; Chuang-Chi Liaw, MD
Original Article 167 Intravenous Ondansetron plus Intravenous Dexamethasone with Different Ondansetron Dosing Schedules during Multiple Cycles of Cisplatin-based Chemotherapy Ping-Tsung Chen, MD; Chuang-Chi
More informationAntiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild and Moderately Emetogenic Chemotherapy
218 Journal of Pain and Symptom Management Vol. 18 No. 3 September 1999 Original Article Antiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild
More informationreceiving high-dose cisplatin
British Journal of Cancer (1996) 73, 217-221 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 0 Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin
More informationDefining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity
More informationOral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy
Oral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy CARL J. FRIEDMAN, a HOWARD A. BURRIS III, b KAREN YOCOM, a LINDA
More informationA Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy
A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy JESSE I. SPECTOR, a ERIC P. LESTER, b ERIC M. CHEVLEN,
More informationDrug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc.
Drug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc. Pharmacology: Aprepitant (previously known as MK-0839 and L-754030) is a new molecular entity that is the first in a new therapeutic class,
More informationThe New England Journal of Medicine REDUCTION OF CISPLATIN-INDUCED EMESIS BY A SELECTIVE NEUROKININ-1 RECEPTOR ANTAGONIST
REDUCTION OF CISPLATIN-INDUCED EMESIS BY A SELECTIVE NEUROKININ-1 RECEPTOR ANTAGONIST RUDOLPH M. NAVARI, M.D., RICK R. REINHARDT, M.D., PH.D., RICHARD J. GRALLA, M.D., MARK G. KRIS, M.D., PAUL J. HESKETH,
More informationemesis: a randomised double blind trial
Br. J. Cancer (1989), 6, 759-763 '." The Macmillan Press Ltd., 1989 Br. J. Cancer (1989), 6, 759-763 1989 The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationUsing a Simple Diary for Management of Nausea and Vomiting During Chemotherapy
Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy Problem identification Nausea and vomiting (N&V) are frequent complications following chemotherapy, even when taking 5-HT3
More informationMOLECULAR AND CLINICAL ONCOLOGY 2: , 2014
MOLECULAR AND CLINICAL ONCOLOGY 2: 375-379, 2014 Palonosetron exhibits higher total control rate compared to first generation serotonin antagonists and improves appetite in delayed phase chemotherapy induced
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
Thalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Geng Song, Qian He, Fanfan Li, and Nianfei Wang Department of Oncology, The Second Affiliated
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Evaluation of Medicines for Human Use London, 17 February 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON NON-CLINICAL AND CLINICAL DEVELOPMENT OF
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationPERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER
June 2004 PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 DELAYED EMESIS WORKING
More informationDELAYED EMESIS: AFTER ACUTE AND MODERATELY EMETOGENIC CHEMOTHERAPY. Matti S. Aapro on behalf of the PERUGIA Writing Committee
The Perugia Consensus On Nausea And Vomiting: Chemotherapy- Induced Delayed Emesis Matti Aapro, MD Objectives 1. Briefly describe the mechanisms of CT induced delayed emesis 2. Efficacy of standard therapy
More informationThe influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting
Journal of BUON 12: 245-252, 2007 2007 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting T. Sarcev
More informationCopyright, 1995, by the Massachusetts Medical Society
Copyright, 1995, by the Massachusetts Medical Society Volume 332 JANUARY 5, 1995 Number 1,, OR BOTH FOR THE PREVENTION OF NAUSEA AND VOMITING DURING CHEMOTHERAPY FOR CANCER THE ITALIAN GROUP FOR ANTIEMETIC
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationDose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy
Br. J. Cancer (I 994), 69, 967 97 0 Macmillan Press Ltd., 994 Br. J. Cancer (994), 69, 967-97 Macmillan Press Ltd., 994 Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy
More informationThe incidence of chemotherapy-induced emesis is difficult to determine, because the cause is likely to be multifactorial and include factors such as
Pediatric Hematology and Oncology, 21: 227 235, 2004 Copyright C Taylor & Francis Inc. ISSN: 0888-0018 print / 1521-0669 online DOI: 10.1080/08880010490427351 SINGLE-DOSE ORAL GRANISETRON VERSUS MULTIDOSE
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationDrug Class Review on Newer Antiemetics
Drug Class Review on Newer Antiemetics Final Report January 2006 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationDelayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
Support Care Cancer (2011) 19 (Suppl 1):S57 S62 DOI 10.1007/s00520-010-1039-y SPECIAL ARTICLE Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) Fausto Roila & David
More informationClinical Review Report
CADTH COMMON DRUG REVIEW Clinical Review Report Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma) Indication: In combination with dexamethasone, onceper-cycle treatment for the prevention
More informationInternational Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany. What was hot at MASCC/ISOO Annual Meeting this year?
International Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany What was hot at MASCC/ISOO Annual Meeting this year? Supportive Care Makes Excellent Cancer Care Possible. This slogan
More informationPrevention CINV (highly emetogenic) Prevention PONV
Reviews/Evaluations 5-Hydroxytryptamine3 (5-HT3) Receptor Antagonists Generic Name Brand Name Manufacturer Dolasetron Anzemet Aventis Granisetron Kytril Roche Ondansetron Zofran GlaxoSmithKline I. FDA
More informationNausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea
Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN,
More informationPREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK
PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK HISTORY OF ANTIEMETICS 1979 A corticosteroid is superior
More informationImpact of Chemotherapy-Induced Nausea and Vomiting on Quality of Life in Indonesian Patients With Gynecologic Cancer
ORIGINAL STUDY Impact of Chemotherapy-Induced Nausea and Vomiting on Quality of Life in Indonesian Patients With Gynecologic Cancer Dyah Aryani Perwitasari, MSi,*Þþ Jarir Atthobari, PhD,Þ Mustofa Mustofa,
More informationDrug: Aprepitant (Emend ) Date of Review: 4/01/10
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010
More informationPediatric Trials 23/04/2018. Disclosures. Nausea and Vomiting Control in Adults and Children: Mind the Gap! Learning Objectives
Nausea and Vomiting Control in Adults and Children: Mind the Gap! Disclosures No relevant conflicts of interest Lee Dupuis, RPh, PhD May 5, 2018 2 Learning Objectives At the end of this presentation, attendees
More informationOrganizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD
PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 Organizing and Overall Meeting
More informationStudent Project PRACTICE-BASED RESEARCH
Pharmacist-Driven Management of Chemotherapy Induced Nausea and Vomiting in Hospitalized Adult Oncology Patients. A Retrospective Comparative Study Ramy Elshaboury, PharmD 1 and Kathleen Green, PharmD,
More informationRoberto Sabbatini*, Massimo Federico*, Luca Baldini, Fausto Barbieri*, Maria Teresa Maiolo, Vittorio Silingardi*
original paper Haematologica 1995; 80:416-420 A RANDOMIZED, DOUBLE-BLIND, CROSS-OVER STUDY COMPARING A LEVOSULPIRIDE-BASED AND A METOCLOPRAMIDE-BASED COMBINA- TION IN THE PREVENTION OF PROMECE-CYTABOM-INDUCED
More informationEuropean Medicines Agency
European Medicines Agency SCIENTIFIC DISCUSSION 1. Introduction Emend is an oral substance P, aka human neurokinin 1 (NK-1)-receptor antagonist. Mammalian tachykinin substance P (SP) that binds to the
More informationChemotherapy Induced Nausea and Vomiting
Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting
More informationManagement of chemotherapyinduced nausea and vomiting
p h a r m a c o t h e r a p y Management of induced nausea and vomiting Authors Key words F. Van Ryckeghem and S. Van Belle Antiemetic therapy,, prevention Summary Chemotherapy-induced nausea and vomiting
More informationOriginal. Key words : breast cancer, chemotherapy-induced nausea and vomiting, quality of life, Functional Living Index Emesis
Showa Univ J Med Sci 30 2, 285 296, June 2018 Original The Impact on Quality of Life of Highly Effective Antiemetic Therapy among Breast Cancer Patients Receiving Anthracycline Plus Cyclophosphamide-based
More informationCost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer
Critical Reviews in Oncology/Hematology 32 (1999) 105112 www.elsevier.com/locate/critrevonc Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic
More informationIvyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract
1371 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(8): 1371-1377. doi: 10.7150/jca.17102 Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior
More informationOncologist. The. Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control FREDERICK M.
The Oncologist Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control FREDERICK M. SCHNELL Central Georgia Hematology and Oncology Associates, Macon, Georgia, USA Key Words.
More information'." Macmillan Press Ltd., 1993 Br. J. Cancer (1993), 68,
Br. J. Cancer (1993), 68, 176-180 '." Macmillan Press Ltd., 1993 Br. J. Cancer (1993), 68, 176-180 1993 The control of acute cisplatin-induced emesis - a comparative study of granisetron and a combination
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationDavid G. Frame, PharmD. he etiology of nausea and vomiting is multifactorial,
r e v i e w Best Practice Management of CINV in Oncology Patients: I. Physiology and Treatment of CINV Multiple Neurotransmitters and Receptors and the Need for Combination Therapeutic Approaches David
More informationZOFRAN TABLETS GlaxoSmithKline
ZOFRAN TABLETS GlaxoSmithKline Ondansetron QUALITATIVE AND QUANTITATIVE COMPOSITION ZOFRAN tablets 4 mg: Each tablet contains ondansetron 4 mg as hydrochloride dihydrate. ZOFRAN tablets 8 mg: Each tablet
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationAn Evidence Practice Gap in Antiemetic Prescription with Chemotherapy
2014 An Evidence Practice Gap in Antiemetic Prescription with Chemotherapy Chepsy C Philip 1*, Biju George 1 1 Department of Clinical Haematology, CMC Vellore, Tamil Nadu, India. ARTICLE INFO Article type:
More informationThe New England Journal of Medicine
ALONE OR IN COMBINATION WITH ONDANSETRON FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING INDUCED BY CHEMOTHERAPY THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH* ABSTRACT Background The prevention of delayed
More informationSTEROID GUIDELINES AUDIT RESULTS
STEROID GUIDELINES AUDIT RESULTS 27 patients were under active follow up between the audit dates. Notes for all these were audited. 59% (163) were not on steroids during this time 21% (57) were already
More informationESMO HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE
ESMO 2016 - HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE FLORIAN SCOTTE Cancer Department Supportive Care in Cancer Unit Georges Pompidou European Hospital Paris France esmo.org DISCLOSURE SLIDE Consultant
More informationFINAL CDEC RECOMMENDATION
FINAL CDEC RECOMMENDATION PALONOSETRON CAPSULE (Aloxi Eisai Limited) Indication: Chemotherapy-Induced Nausea and Vomiting Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that oral
More informationThe Role of Patients Expectations in the Development of Anticipatory Nausea Related to Chemotherapy for Cancer
Vol. 22 No. 4 October 2001 Journal of Pain and Symptom Management 843 Original Article The Role of Patients Expectations in the Development of Anticipatory Nausea Related to Chemotherapy for Cancer Jane
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationANTICANCER RESEARCH 27: (2007)
A Randomized Trial to Compare the Efficacy and Safety of Antiemetic Treatment with Ondansetron and Ondansetron Zydis in Patients with Breast Cancer Treated with High-dose Epirubicin D. PECTASIDES 1, U.
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationBRAJACTT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationReview Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced
More informationDexamethasone combined with other antiemetics for prophylaxis after laparoscopic cholecystectomy
Original Research Article Dexamethasone combined with other antiemetics for prophylaxis after laparoscopic cholecystectomy T. Uma Maheswara Rao * Associate Professor, Department of Surgery, Konaseema Institute
More informationSafety and efficacy of a continuous infusion, patient controlled antiemetic pump to facilitate outpatient administration of high-dose chemotherapy
Bone Marrow Transplantation, (1999) 24, 561 566 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt Safety and efficacy of a continuous infusion, patient controlled
More informationResearch Article. Chemotherapy-induced nausea and vomiting in Portugal: incidence versus healthcare provider estimations and effect on quality of life
Research Article Chemotherapy-induced nausea and vomiting in Portugal: incidence versus healthcare provider estimations and effect on quality of life Aim: To compare chemotherapy-induced nausea and vomiting
More informationCost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy
Blackwell Publishing IncMalden, USAVHEValue in Health1098-30152006 Blackwell Publishing20071012331Original ArticleCost-Effectiveness of AprepitantMoore et al. Volume 10 Number 1 2007 VALUE IN HEALTH Cost-Effectiveness
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationI 5-HT = 5-hydroxytryptamine
Special Article History of the Development of Antiemetic Guidelines at Mayo Clinic Rochester CHARLES L. LOPRNZ, MD; STEVEN LORELE J. HANSON, ROBERT RN; E. GRADY, MD; R. ALBERTS, MD; BRADLEY J. CHRSTENSEN,
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationNew Zealand Datasheet
New Zealand Datasheet Name of Medicine ONREX Tablets Ondansetron hydrochloride dihydrate tablets 4mg and 8mg. Presentation ONREX tablets 4 mg: White, circular, biconvex, film coated tablet debossed with
More information9/3/2014. Conflict of Interest Disclosures. Learning Objectives. Definitions of Nausea/Vomiting. Definitions of Nausea/Vomiting
Conflict of Interest Disclosures LeAnn B. Norris Teva Pharmaceuticals Last Chance Webinar 2014 Oncology Supportive Care LeAnn B. Norris, PharmD, BCPS, BCOP Assistant Professor South Carolina College of
More informationChemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study
Support Care Cancer (2012) 20:107 117 DOI 10.1007/s00520-010-1073-9 ORIGINAL ARTICLE Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study Doranne L. Hilarius
More informationA prospective study of gastrointestinal radiation therapy-induced nausea and vomiting
Support Care Cancer (2014) 22:1493 1507 DOI 10.1007/s00520-013-2104-0 ORIGINAL ARTICLE A prospective study of gastrointestinal radiation therapy-induced nausea and vomiting Michael Poon & Kristopher Dennis
More informationCurrent position of 5HT 3 antagonists and the additional value of NK 1 antagonists; a new class of antiemetics
British Journal of Cancer (2003) 88, 1823 1827 All rights reserved 0007 0920/03 $25.00 www.bjcancer.com Minireview Current position of 5HT 3 antagonists and the additional value of NK 1 antagonists; a
More informationChemotherapy-induced nausea and vomiting
Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children Veerendra Patil, MD, FNB; Harsha Prasada, MD, DCH,
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationPrevention of chemotherapy induced nausea and vomiting in pediatric cancer patients
REVIEW ARTICLE Prevention of chemotherapy induced nausea and vomiting in pediatric cancer patients Shubham Roy 1, Rashi Kulshrestha 2, Abhishek Shankar 3, Goura Kishor Rath 4, Vipin Kharade 4 1 Department
More informationVinorelbine (Navelbine ) plus Capecitabine (Xeloda ) Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Vinorelbine 60 to 80 mg/m 2 Oral N/A Stat Dose Days 1 to 14 Capecitabine 1000 mg/m 2 twice a day* Vinorelbine Capecitabine protocolcrp11b0024
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationONDANSETRON HCl AMNOSET 4 AMNOSET 6
For the use of a Registered Medical Practitioner, Hospital or a Laboratory only. Product Monograph ONDANSETRON HCl AMNOSET 4 AMNOSET 6 4mg Film-Coated Tablet 8mg Film-Coated Tablet Antiemetic Manufactured
More informationA Study on Evaluation of Anti-Emetics in the Prevention of Chemotherapy Induced Nausea and Vomiting in Cancer Patients in A Tertiary Care Hospital
Original Article A Study on Evaluation of Anti-Emetics in the Prevention of Chemotherapy Induced Nausea and Vomiting in Cancer Patients in A Tertiary Care Hospital Elizabeth Phoeba Paul 1*, Ahana Behanan
More informationAntiemetics in chemotherapy
Antiemetics in chemotherapy Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission Date
More informationANTIEMETIC RESEARCH AND PROGRESS: Richard J. Gralla, MD, FACP Professor of Medicine Albert Einstein College of Medicine Bronx, New York
ANTIEMETIC RESEARCH AND PROGRESS: Richard J. Gralla, MD, FACP Professor of Medicine Albert Einstein College of Medicine Bronx, New York THE FUTURE OF ANTIEMETICS Fausto Roila Medical Oncology, Terni, Italy
More informationMale/Female Differences in Drug-induced Emesis and Motion Sickness in Suncus murinus
PII S0091-3057(96)00389-9 Pharmacology Biochemistry and Behavior, Vol. 57, No. 4, pp. 721 725, 1997 1997 Elsevier Science Inc. Printed in the USA. All rights reserved 0091-3057/97 $17.00.00 Male/Female
More informationMorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose
More informationZOFRAN INJECTION GlaxoSmithKline
ZOFRAN INJECTION GlaxoSmithKline Ondansetron QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml of aqueous solution contains 2 mg ondansetron as hydrochloride dihydrate. PHARMACEUTICAL FORM A clear, colourless,
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationAnticipatory nausea and emesis, and psychological morbidity: assessment
Br. J. Cancer '." r. J. Cancer (1992), 66, (I Macmillan Press Ltd., 1992 862 992), 86666, 862 866 t~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
More informationGI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi
GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics Dr. Alia Shatanawi 11-04-2018 Drugs used in Irritable Bowel Syndrome Idiopathic, chronic, relapsing disorder characterized by abdominal discomfort
More informationIJMDS January 2017; 6(1) Dr Robina Makker Associate professor 2 Dr Amit Bhardwaj
Original Article Comparative efficacy of ondansetron versus granisetron to prevent perioperative nausea and vomiting in patients undergoing gynaecological surgery under spinal anaesthesia Makker R 1, Bhardwaj
More informationPrevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
Annals of Oncology 17: 20 28, 2006 doi:10.1093/annonc/mdj078 Published online 28 November 2005 Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationOverview of the neurokinin-1 receptor antagonists
Editorial Page 1 of 6 Overview of the neurokinin-1 receptor antagonists Rudolph M. avari Division of Hematology Oncology, School of Medicine, University of Alabama Birmingham, Birmingham, AL, USA Correspondence
More informationThe Journal of International Medical Research 2011; 39:
The Journal of International Medical Research 2011; 39: 399 407 A Randomized, Double-blind Trial of Palonosetron Compared with Ondansetron in Preventing Postoperative Nausea and Vomiting after Gynaecological
More informationGranisetron Hydrochloride Tablets USP, 1 mg
Granisetron Hydrochloride Tablets USP, 1 mg Rx only DESCRIPTION Granisetron Hydrochloride Tablets USP contain granisetron hydrochloride, an antinauseant and antiemetic agent. Chemically it is endo-n-(9-methyl-9-azabicyclo
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting Tang J, Wang B G, White P F, Watcha M F,
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More information